Exelixis is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new products for difficult-to-treat cancers. Discovery efforts have resulted in 4 approved products available worldwide. The cabozantinib clinical development program focuses on evaluation of potential activity in new tumor types as well as combinations with other agents through ISTs, CTEP collaboration, and pivotal studies, including the COSMIC and CONTACT clinical trial programs. Exelixis continues to invest in expansion of our product pipeline through internal drug discovery and strategic business development opportunities. The educational resources provided on this site may include information about a product or use that is not approved by the FDA.
Click each of the following images to access a downloadable PDF and/or brochures.
KidneyCAN thanks Exelixis for their generous contribution in support of #KCRS20 as a Founding Partner.